The Rubella (German Measles) drugs in development market research report provides comprehensive information on the therapeutics under development for Rubella (German Measles), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Rubella (German Measles). Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Rubella (German Measles) and features dormant and discontinued products.
GlobalData tracks 12 drugs in development for Rubella (German Measles) by 11 companies/universities/institutes. The top development phase for Rubella (German Measles) is phase iii with four drugs in that stage. The Rubella (German Measles) pipeline has ten drugs in development by companies and two by universities/ institutes. Some of the companies in the Rubella (German Measles) pipeline products market are: Beijing Minhai Biotechnology, Vaxxas and Daiichi Sankyo.
The key mechanisms of action in the Rubella (German Measles) pipeline product include The Rubella (German Measles) pipeline products include two routes of administration with the top ROA being Subcutaneous and two key molecule types in the Rubella (German Measles) pipeline products market including Live Attenuated Vaccine, and Vaccine.
Rubella (German Measles) overview
Rubella, also known as German measles, is an acute, contagious viral infection. The rubella virus is transmitted by airborne droplets when infected people sneeze or cough. Symptoms include fever, headache, stuffy or runny nose, red and inflamed eyes, aching joints, and enlarged, tender lymph nodes at the base of the skull, the back of the neck, and behind the ears.
For a complete picture of Rubella (German Measles)’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
